162 related articles for article (PubMed ID: 38886179)
1. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
3. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
4. Long-acting injectable antiretrovirals for HIV treatment and prevention.
Spreen WR; Margolis DA; Pottage JC
Curr Opin HIV AIDS; 2013 Nov; 8(6):565-71. PubMed ID: 24100877
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
[TBL] [Abstract][Full Text] [Related]
6. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
Kovač L; Časar Z
Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
[No Abstract] [Full Text] [Related]
7. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of cabotegravir for HIV treatment and prevention.
Canetti D; Spagnuolo V
Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
[No Abstract] [Full Text] [Related]
9. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
[TBL] [Abstract][Full Text] [Related]
10. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
[TBL] [Abstract][Full Text] [Related]
12. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
[TBL] [Abstract][Full Text] [Related]
13. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
Flexner C; Owen A; Siccardi M; Swindells S
Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
[TBL] [Abstract][Full Text] [Related]
14. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
[TBL] [Abstract][Full Text] [Related]
15. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
[TBL] [Abstract][Full Text] [Related]
16. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection.
Ullah Nayan M; Sillman B; Hasan M; Deodhar S; Das S; Sultana A; Thai Hoang Le N; Soriano V; Edagwa B; Gendelman HE
Adv Drug Deliv Rev; 2023 Sep; 200():115009. PubMed ID: 37451501
[TBL] [Abstract][Full Text] [Related]
17. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
[TBL] [Abstract][Full Text] [Related]
18. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
[TBL] [Abstract][Full Text] [Related]
19. Long-acting antiviral agents for HIV treatment.
Margolis DA; Boffito M
Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
[TBL] [Abstract][Full Text] [Related]
20. Cabotegravir long-acting for HIV-1 prevention.
Andrews CD; Heneine W
Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]